Orphan drugs have gained increased attention in recent years from patients and drug developers. However, developing therapeutic options for patients affected by rare genetic diseases is challenging- incorporating additional dimensions of understanding the disease beyond genotype and phenotype is critical for success.
Watch our recent webinar to learn about innovative methods to tackle the challenges of orphan drugs in early stage development, clinical trial enrollment, and market development. Throughout the webinar, our speakers will share case studies of solutions in our collaborative fight to improve outcomes for patients and their families.
The webinar was organized in cooperation with Pink Sheet, the world’s premier news source for biopharma regulations.
- An integrated approach to target discovery & validation
- Rapid biomarker development for the identification, recruitment & stratification of patients in clinical studies
- The best tools to monitor treatment efficacy & improve health economic outcome
- Accurate, cost-effective approaches to screening high-risk populations
Justin, as Senior Vice President of Business Development at CENTOGENE, leads a global […]
Oved serves as CENTOGENE’s Chief Business Officer, where he has the overall […]
Prof. Peter Bauer, M.D., serves as CENTOGENE’s Chief Genomic Officer, where he combines […]